Ask AI
ProCE Banner Activity

CE

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

Slideset

Downloadable slides on the efficacy and safety of targeting BCMA in early relapsed/refractory multiple myeloma and the optimal management of the associated adverse events.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: April 29, 2026

Expiration: October 28, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from GSK.

GSK

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with relapsed/refractory multiple myeloma.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence to optimize the use of BCMA-targeted agents in patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the rationale for targeting BCMA to improve outcomes in patients with early R/R MM

  • Summarize recent updates on BCMA-targeted therapies for R/R MM in treatment discussions with physicians and patients

  • Employ evidence-based strategies to monitor and manage ocular toxicity associated with BCMA-targeted antibody–drug conjugates for early R/R MM in collaboration with the multidisciplinary care team

Financial Disclosures

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP: consultant/advisor/speaker: Genentech, Genmab, GSK, Incyte, Johnson & Johnson, Lilly, Sanofi.

Anthony Perissinotti, PharmD, BCOP: consultant/advisor/speaker: Amgen, Jazz, Servier.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 29, 2026, through October 28, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-012-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.0 contact hours (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.